Department of Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
J Biochem Mol Toxicol. 2024 Dec;38(12):e23842. doi: 10.1002/jbt.23842.
Breast cancer represents a significant health burden globally, necessitating ongoing advancements in treatment strategies for improved patient outcomes. Immunotherapy, particularly targeting immune checkpoints like programmed death-1 (PD-1), has emerged as a promising approach in cancer therapy. This study focuses on elucidating the role of PD-1 in modulating the IFN-γ-CXCL9/10-CXCR3 signaling axis within the breast cancer microenvironment. By investigating the synergistic effects of PD-1 inhibitors in combination with Inetetamab, our research aims to uncover novel therapeutic targets for enhancing immunotherapy efficacy in breast cancer. Through comprehensive experimental analysis, we seek to deepen our understanding of the intricate molecular mechanisms underlying immune regulation in breast cancer, thereby paving the way for more effective and sustainable treatment strategies. Ultimately, our study endeavors to establish a robust theoretical framework that can guide the development of innovative clinical interventions, aiming for improved outcomes in breast cancer patients.
乳腺癌是全球范围内的重大健康负担，需要不断改进治疗策略以改善患者的预后。免疫疗法，特别是针对免疫检查点如程序性死亡受体 1（PD-1）的免疫疗法，已成为癌症治疗的一种有前途的方法。本研究旨在阐明 PD-1 在调节乳腺癌微环境中 IFN-γ-CXCL9/10-CXCR3 信号轴中的作用。通过研究 PD-1 抑制剂与 Inetetamab 联合使用的协同作用，我们的研究旨在为增强乳腺癌免疫治疗的疗效寻找新的治疗靶点。通过全面的实验分析，我们旨在深入了解乳腺癌免疫调节的复杂分子机制，从而为更有效和可持续的治疗策略铺平道路。最终，我们的研究努力建立一个强大的理论框架，指导创新的临床干预措施的发展，旨在改善乳腺癌患者的预后。
